A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

Following the onset of nonarteritic anterior ischemic optic neuropathy, regular stroke workup may be necessary.

Compr Ophthalmol Update. 2005;6(1):11-21. As can be seen in Table 2, untreated cases of TON improve even when the initial vision is no light perception. This rate of spontaneous visual improvement ...

Patients with vs without nonarteritic anterior ischemic optic neuropathy demonstrated an elevated risk for stroke. Individuals with vs without nonarteritic anterior ischemic optic neuropathy ...

With the exception of giant cell arteritis and hypertensive retinopathy, fundal signs related to systemic vasculitides are uncommon, or even rare. The vasculitic process typically affects the ...

Objective Evaluating the potential role of neuromuscular ultrasonography (NMUS) in assessing optic nerve affection in patients with systemic lupus erythematosus (SLE), compared with healthy controls ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy, even when ...

An increased risk for NAION was seen among participants with T2D, overweight/obesity receiving semaglutide vs non-GLP1-RA meds. Jimena Tatiana Hathaway, M.D., M.P.H., from the Harvard T.H. Chan ...

TUESDAY, Jan. 14, 2025 (HealthDay News) -- Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes ...